Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 8/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 8/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 8/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19973512 | 1.00 | TAS1R3 (0.40) | TAS1R3TAS1R1TAS1R2KDM4EFNTA | |
| SCHEMBL19973513 | 1.00 | TAS1R3 (0.40) | TAS1R3TAS1R1TAS1R2KDM4EFNTA | |
| SCHEMBL20509848 | 0.93 | DRD2 (0.36) | TAS1R3TAS1R1TAS1R2KDM4E | |
| SCHEMBL21189270 | 0.85 | TAS1R3 (0.41) | TAS1R3TAS1R1TAS1R2KDM4EMEN1 | |
| SCHEMBL354999 | 0.84 | TAS1R3 (0.36) | TAS1R3TAS1R1TAS1R2KDM4EHSD17B2 | |
| SCHEMBL3583095 | 0.82 | TAS1R3 (0.38) | TAS1R3TAS1R1TAS1R2LMNACA1 | |
| SCHEMBL19973628 | 0.80 | MAPT (0.40) | TAS1R3TAS1R1TAS1R2LMNAKMT2A | |
| SCHEMBL19973627 | 0.80 | MAPT (0.40) | TAS1R3TAS1R1TAS1R2LMNAKMT2A | |
| SCHEMBL19973626 | 0.80 | MAPT (0.40) | TAS1R3TAS1R1TAS1R2LMNAKMT2A | |
| SCHEMBL19973539 | 0.78 | TRPV1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-11 | — | — | US | disclosed |
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2019-07-25 | — | — | US | disclosed |
| WO-2018052967-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | CBX8, HAVCR2, HCCS | TAS1R3 3760/4885TAS1R1 3802/4885TAS1R2 3995/4885 |
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | CBX8, HAVCR2, HCCS | TAS1R3 3760/4885TAS1R1 3802/4885TAS1R2 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.